Last reviewed · How we verify
Cimzia
At a glance
| Generic name | Cimzia |
|---|---|
| Also known as | certolizumab pegol, Certolizumab Pegol, CDP870, CZP, Certolizumab-pegol |
| Sponsor | University of Washington |
| Target | Tumor necrosis factor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Ankylosing spondylitis
- Crohn's disease
- Erythrodermic psoriasis
- Plaque psoriasis
- Psoriasis with arthropathy
- Psoriatic arthritis
- Pustular psoriasis
- Rheumatoid arthritis
Common side effects
- Upper respiratory tract infection
- Rash
- Urinary tract infection
- Arthralgia
Serious adverse events
- Tuberculosis infections
- Abdominal pain
- Diarrhea
- Intestinal obstruction
- Pyrexia
- Urticaria
- Pneumonia
- Myocardial infarction
- Cardiac failure
- Stroke
Key clinical trials
- A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- Stand UP to Rheumatoid Arthritis (SUPRA) (NA)
- Lipids, Inflammation, and CV Risk in RA
- Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (PHASE4)
- Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery (PHASE2)
- A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis (PHASE2)
- The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cimzia CI brief — competitive landscape report
- Cimzia updates RSS · CI watch RSS
- University of Washington portfolio CI